WASHINGTON — The pharmaceutical industry’s massive lobbying operation has a well-earned reputation for maintaining a united front on most of the major policy proposals that could affect drug makers and their bottom lines. But as the industry eyes the burgeoning biosimilar market, that united front is starting to crack.
For years, branded pharmaceutical and biotech manufacturers — largely represented by PhRMA and BIO — have clashed most often with generic manufacturers, largely represented by their own Association for Accessible Medicines.
About the Author Reprints
